Quick View
| Metric | Current Period | Same Period of Previous Year | YoY |
|---|---|---|---|
| Revenue | ¥45.4B | ¥45.4B | +0.0% |
| Operating Income | ¥4.9B | ¥7.0B | −29.9% |
| Ordinary Income | ¥4.9B | ¥7.0B | −29.1% |
| Net Income | ¥4.6B | ¥4.5B | +1.8% |
| ROE | 6.5% | 6.8% | - |
Executive Summary
For the cumulative Q3 of the fiscal year ending March 2026, the Company maintained Revenue at approximately the same level as the same period of the previous year, while Operating Income declined substantially due to increases in personnel and raw material costs. The results represented higher Revenue and lower earnings (effectively flat Revenue and lower earnings), with Revenue of ¥45.4B (+0.0% YoY), Operating Income of ¥4.9B (down 29.9%), and Ordinary Income of ¥4.9B (down 29.1%). Meanwhile, Net Income increased 1.8% to ¥4.6B, primarily due to a lower tax burden (effective tax rate: 7.4%). The primary factors behind the decline in earnings were slower sales of writing instrument-related products in the China region and higher costs in the core Techno Products Business.
Factors Affecting Results
【Revenue】Revenue was ¥45.4B, essentially flat at +0.0% YoY. While the Medical Products Business grew 3.8%, the core Techno Products Business declined 1.4% due to the slowdown in writing instrument-related sales in the China region, with the two businesses effectively offsetting each other.
【Profit and Loss】Operating Income was ¥4.9B (down 29.9%), and Ordinary Income was ¥4.9B (down 29.1%), primarily due to increases in personnel and raw material costs. Extraordinary items were negligible (extraordinary income of ¥0.05B and extraordinary loss of ¥0.01B), indicating limited impact from temporary factors. Net Income increased 1.8% to ¥4.6B, in contrast to the declines in Operating Income and Ordinary Income, mainly because income taxes and other taxes fell substantially from ¥2.4B in the previous year to ¥0.4B in the current period. This divergence was attributable to tax effects and does not offset the decline in the profitability of the core business. In conclusion, the Company is in a period of higher Revenue (effectively flat) and lower earnings.
Segment Analysis
Segment Operating Income was ¥6.0B for the Techno Products Business (down 30.1%) and ¥1.2B for the Medical Products Business (up 15.6%). The Techno Products Business is the core business, accounting for 71.3% of the Revenue mix. Although its profit margin was high at 18.6%, profit declined due to slower demand for writing instrument-related products in the China region and higher costs, making it the primary cause of the deterioration in overall results. Despite accounting for 28.7% of the Revenue mix, the Medical Products Business achieved higher Revenue and earnings, supported by promotional activities at domestic and overseas exhibitions and academic conferences, and improved its profit margin to 8.8%. The difference in profit margins between the two businesses (18.6% versus 8.8%) is substantial, and the profitability of the Techno Products Business determines overall Company earnings.
Key Financial Metrics
ROE was 6.5%, while the Operating Income margin was 10.7% (estimated at approximately 15.3% for the same period of the previous year, representing a deterioration of approximately 4.6pt). Operating Cash Flow (OCF) and FCF cannot be evaluated because they have not been disclosed. Although there is no data for a direct comparison of capital expenditures and depreciation, the medium-term management plan calls for investments of at least ¥1.5B over 3 years. The Equity Ratio was 71.2% (67.1% in the previous year), and the current ratio was extremely high at 459.1%.
Cash Flow Analysis
No disclosed data is available for Operating Cash Flow (OCF), investing CF, or financing CF, so FCF and direct cash-generation capacity cannot be evaluated. However, cash and deposits were ¥25.4B, approximately 1.76 times current liabilities of ¥14.4B, indicating substantial short-term financial capacity. Work-in-process inventory was ¥15.5B, the largest component of inventory, and the accumulation of working capital may affect future cash generation.
Earnings Quality
Net Income was ¥4.6B against Ordinary Income of ¥4.9B, so the divergence was not large. However, compared with the same period of the previous year, Ordinary Income declined 29.1% while Net Income increased 1.8%, representing a reversal in direction. This was attributable to the lower income tax burden (¥2.4B in the previous year → ¥0.4B in the current period), with the effective tax rate remaining low at 7.4%. Non-operating income and expenses were each approximately ¥0.2B, less than 1% of Revenue and therefore having a minor impact on the earnings structure. Extraordinary items were also negligible. Overall, it should be noted that the increase in Net Income was essentially due to a temporary reduction in the tax burden and did not reflect the profitability of the core business.
Earnings Forecast and Guidance
Progress toward the full-year forecasts (Revenue of ¥62.0B, Operating Income of ¥7.5B, and Ordinary Income of ¥7.3B) was 73.2% for Revenue, 65.0% for Operating Income, 67.7% for Ordinary Income, and 90.6% for Net Income. Compared with the standard progress rate of 75%, Operating Income was 10.0pt below the benchmark, while Net Income was 15.6pt above it, indicating an imbalance. The delayed progress in Operating Income indicates the need for a recovery in the core business during Q4, and improvement in the profitability of the core business will be key to achieving the full-year forecasts.
Shareholder Returns
The Company’s full-year dividend forecast is ¥35 (including a commemorative dividend of ¥5), and the Payout Ratio based on the full-year Net Income forecast of ¥5.1B is approximately 18.8%. No share buyback has been confirmed, so no assessment is made of the Total Return Ratio. The substantial cash balance (¥25.4B) and low interest-bearing debt (Debt/Capital ratio: 10.4%) support the Company’s financial capacity to pay dividends.
Catalysts
【Short Term】The trend in profit recovery in the core Techno Products Business during Q4 (a recovery in demand for cosmetic pen tips) and confirmation of progress toward the full-year Operating Income forecast.
【Long Term】Progress toward the FY2027 targets under the new medium-term management plan, “Aubex Vision 2027” (Revenue of ¥70B, Operating Income of ¥10B, and ROE of at least 9%), progress on capital expenditures of at least ¥1.5B over 3 years, and developments regarding the acquisition of a site for construction of a new Medical Products Business plant.
Industry Benchmark (Reference; Compiled by the Company)
Industry Benchmark (manufacturing)
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Income Margin | 10.7% | 8.6% (4.3%–12.7%) | +2.1pt |
| Net Income Margin | 10.2% | 6.4% (2.8%–10.3%) | +3.8pt |
Both the Operating Income margin and Net Income margin exceed the industry median, indicating that profitability is relatively high within the industry.
※Source: Compiled by the Company
Risk Factors
-
Deterioration in the profitability of the core business: Segment profit for the Techno Products Business declined 30.1% YoY. If the slowdown in demand for writing instrument-related products in the China region and increases in personnel and raw material costs continue, overall Company earnings may remain under pressure.
-
Accumulation of working capital: Work-in-process inventory of ¥15.5B is the largest component of total inventories, and stagnation in the production process or longer delivery times may affect capital efficiency. The combined amount of trade receivables of ¥12.6B and work-in-process inventory accounts for approximately 27% of total assets.
-
Uncertainty regarding achievement of the full-year forecasts: The progress rate for Operating Income was 65.0%, below the standard progress rate, requiring profit generation in Q4 to exceed that of the same period of the previous year. By region, continued weakness in sales in North America, Central America, and South America also warrants ongoing monitoring.
Key Points from the Earnings Report
-
Net Income increased 1.8% YoY, but this increase was attributable to a substantial decline in the effective tax rate (a lower tax burden than in the previous year), while both Operating Income and Ordinary Income declined by approximately 30%. The recovery of the core business’s profitability will be the key focus for future evaluation.
-
By segment, the decline in the high-margin Techno Products Business (18.6%) weighed on overall Company results, while the lower-margin Medical Products Business (8.8%) provided support through higher earnings. This clearly indicates a change in the earnings structure within the business portfolio and warrants close monitoring.
-
Against a backdrop of strong financial health, including an Equity Ratio of 71.2% and a current ratio of 459.1%, the new medium-term management plan sets out capital expenditures of at least ¥1.5B over 3 years. The balance between growth investment and shareholder returns (Payout Ratio of approximately 18.8%) will be an important structural point to monitor going forward.
This report is an automatically generated earnings analysis document created by an AI through integrated analysis of XBRL earnings summary data and PDF earnings presentation materials. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.
---End of Report---
AI Financial Analysis
Executive Summary
FY2026 Q3 performance was mixed: revenue was stable and net income rose modestly, but operating profitability deteriorated materially. Cumulative Q3 revenue was ¥4.54bn, essentially unchanged year on year. Operating income declined 29.9% year on year to ¥487m. Ordinary income declined 29.1% to ¥494m. Net income nevertheless increased 1.8% to ¥462m, supported by a sharply lower effective tax rate of 7.4%. Gross profit fell 14.1% to ¥1.52bn as cost of sales increased 9.1% despite flat sales. The gross margin compressed by 550bp year on year to 33.5%. The operating margin compressed by approximately 460bp to 10.7%, although it remains within the generally healthy 8-15% manufacturing benchmark range. The core Techno Products business recorded a 1.4% sales decline and a 30.1% decline in segment profit, making it the principal source of consolidated earnings weakness. Medical Products delivered 3.8% revenue growth and 15.6% segment-profit growth, partly offsetting the Techno Products decline. Techno Products remained the core business by segment profit contribution, generating ¥600m of profit versus ¥116m for Medical Products. The annualized DuPont ROE was 8.7%, driven by a 10.2% net margin, 0.605x asset turnover, and conservative 1.40x financial leverage. Net income quality at the operating level is weaker than the headline net-income growth suggests because the tax burden, rather than an expansion of operating earnings, accounted for the divergence. Small extraordinary gains of ¥5m, mainly gains on sales of assets and investment securities, were immaterial at roughly 1% of net income. The balance sheet remains highly liquid, with cash of ¥2.54bn and a 459.1% current ratio. However, annualized working-capital metrics indicate a 76-day DSO, 218-day DIO, and a 280-day cash conversion cycle, requiring close monitoring. Full-year sales progress is 73.2% at Q3, broadly in line with the standard 75% pace, while operating-income progress is 64.9%, 10.1 percentage points below the normal Q3 run rate. Achieving full-year operating-income guidance of ¥750m therefore requires a substantial Q4 recovery in margin and/or volume conversion. The full-year net-income target is already 90.6% achieved, but this stronger progress reflects the unusually low tax charge rather than a comparable level of operating-profit momentum.
Profitability Analysis
The annualized three-factor DuPont ROE is 8.7%, comprising a 10.2% net profit margin, 0.605x asset turnover, and 1.40x financial leverage. The principal earnings change was margin compression, not balance-sheet leverage: operating income declined 29.9% while revenue was flat. Gross margin fell from approximately 39.0% to 33.5%, a 550bp contraction, indicating that higher production costs and/or unfavorable product mix were not recovered through pricing. Operating margin fell from approximately 15.3% to 10.7%, a 460bp contraction. SG&A expenses fell 3.8% to ¥1.03bn, demonstrating some cost containment, but the reduction was insufficient to offset the ¥249m decline in gross profit. The segment pattern points to Techno Products as the source of deleveraging: its revenue declined 1.4% to ¥3.24bn while segment profit fell 30.1% to ¥600m, reducing its segment margin from 26.2% to 18.6%. Medical Products improved, with its segment margin rising from 8.0% to 8.9% on revenue growth of 3.8%. The ¥229m reduction in corporate expenses, from ¥263m to ¥229m, moderated but did not prevent the consolidated operating-profit decline. The 10.2% net margin is stronger than the operating-margin trend implies because the tax burden was only 7.4%, with deferred tax income contributing to the low effective tax rate. The 5-factor DuPont tax burden of 0.926 is favorable, while the 1.024 interest burden reflects net non-operating gains rather than meaningful financing pressure. Interest coverage of 46.85x confirms that interest costs are not constraining profitability. Sustainability of the Q3 net margin depends primarily on restoring gross margin in Techno Products and cannot be inferred solely from the low current-period tax rate.
Growth Assessment
Revenue stability masks a pronounced change in business mix and profitability. Techno Products sales decreased by ¥46m year on year to ¥3.24bn, whereas Medical Products sales increased by ¥48m to ¥1.30bn. Medical Products therefore supplied the entire consolidated revenue stabilization, but its smaller profit base could not offset the earnings decline in the core Techno Products business. Consolidated segment profit decreased 25.3% to ¥716m, led by the ¥258m decline in Techno Products segment profit. The full-year sales forecast of ¥6.20bn implies Q4 revenue of approximately ¥1.66bn, broadly consistent with the average quarterly revenue pace achieved through Q3. Full-year operating-income guidance of ¥750m implies Q4 operating income of approximately ¥263m, versus a cumulative Q3 operating margin of 10.7%; this requires a notably stronger quarterly margin than the year-to-date result. Full-year ordinary-income progress is 67.7%, 7.3 percentage points below the standard 75% Q3 pace. Full-year net-income progress is 90.6%, which provides earnings-target support but is not equivalent to operating-profit outperformance. Foreign-exchange gains were ¥13m, equivalent to about 2.7% of operating income, providing a modest non-operating contribution. The near-term growth outlook is consequently tied to normalization of Techno Products profitability, continued Medical Products growth, and conversion of elevated work-in-process into shipments.
Financial Health
Financial health is strong on liquidity and conservative on reported leverage. Current assets of ¥6.63bn exceeded current liabilities of ¥1.44bn by ¥5.19bn, resulting in working capital of ¥5.19bn and a current ratio of 459.1%. The quick ratio was also very robust at 441.2%, supported by ¥2.54bn of cash and deposits. Cash alone exceeded current liabilities by approximately 1.76x, limiting near-term refinancing and maturity-mismatch risk. Debt-to-equity was 0.40x and debt-to-capital was 10.4%, both comfortably below conservative solvency thresholds. Long-term loans were ¥827m, while current portions of long-term loans were ¥506m; the sizeable liquidity buffer substantially covers these obligations. Lease obligations totaled approximately ¥63m, consisting of ¥19m current and ¥44m non-current obligations. Interest coverage of 46.85x indicates ample capacity to service debt. Total equity increased 6.2% year on year to ¥7.12bn, raising the equity ratio to 71.2% from 68.1%. Net defined-benefit liabilities of ¥423m remain a meaningful long-term obligation relative to reported loans, but are well supported by the equity base. Intangible assets increased 34.9% year on year to ¥45m, but represented only 0.5% of total assets and therefore do not create material balance-sheet concentration risk. PPE represented 29.7% of assets, including land of ¥1.48bn, supporting a tangible asset base.
Notable B/S Changes
Intangible assets: +¥12m (+34.9%) to ¥45m — the percentage increase is notable, but the balance remains only 0.5% of total assets and does not indicate material intangible-asset concentration. Raw materials: +¥102m (+20.5%) to ¥602m — increased procurement inventory adds to working-capital requirements and heightens exposure to input-cost movements and demand-forecast accuracy.
Cash Flow Quality
The working-capital profile is the principal cash-conversion concern. Annualized DSO of 76 days exceeds the 60-day warning threshold, indicating relatively slow collection of trade and electronically recorded receivables. Annualized DIO of 218 days is substantially above the 90-day warning level and indicates a large inventory commitment relative to sales and cost of sales. The annualized cash conversion cycle of 280 days is well above the 120-day warning benchmark, increasing the amount of capital tied up in operations. Work in process was ¥1.55bn and represented 64.2% of manufacturing inventory, above the 40% warning threshold. The high WIP ratio is consistent with a production-flow bottleneck, lengthy manufacturing cycle, delayed conversion to finished-goods sales, or project timing exposure. Raw materials increased 20.5% year on year to ¥602m, adding further exposure to procurement-cost and demand-forecast risks. Finished goods increased 8.2% to ¥259m. Trade receivables declined 3.0% to ¥1.26bn, but electronically recorded monetary claims increased to ¥196m from ¥107m, leaving aggregate customer-credit exposure elevated in days terms. Electronic payables rose to ¥384m from ¥327m, providing some supplier-financing support, but not enough to offset the long inventory and receivable cycle. A sustained reduction in WIP and inventory days would be important evidence that operating earnings can translate more efficiently into cash.
Dividend Sustainability
The full-year dividend forecast is ¥35 per share, compared with forecast EPS of ¥185.44. This implies a forecast dividend payout ratio of approximately 18.9%, well below the 60% sustainability benchmark. The payout is therefore modest relative to forecast earnings and supported by the company’s substantial liquidity, including ¥2.54bn of cash and deposits. Book value per share was ¥2,601, underpinned by total equity of ¥7.12bn. Retained earnings increased to ¥4.69bn from ¥4.33bn year on year, reinforcing internal funding capacity. The main factor to monitor for dividend coverage is not the stated earnings payout ratio but whether the extended inventory and WIP cycle absorbs cash that could otherwise be available for shareholder distributions and capital investment. The forecast dividend is aligned with a conservative balance-sheet posture, provided that the Q4 operating-profit recovery required by guidance is achieved.
Risk Assessment
Business risks include High priority — Techno Products profitability risk: revenue declined 1.4% while segment profit fell 30.1%, cutting its segment margin by 760bp to 18.6%. As the largest segment by revenue and profit, further cost inflation, unfavorable mix, or weak demand in this business would materially affect consolidated earnings., High priority — Manufacturing working-capital risk: annualized DSO of 76 days, DIO of 218 days, and a 280-day cash conversion cycle indicate a prolonged operating cycle and greater sensitivity to shipment delays or customer collection timing., High priority — Production-flow risk: WIP of ¥1.55bn represents 64.2% of inventory, above the 40% warning threshold. This may indicate a production bottleneck, extended manufacturing lead times, or delayed project completion, which could defer revenue recognition and elevate obsolescence risk., Medium priority — Input-cost and pricing risk: gross margin declined 550bp despite flat sales, showing that production-cost or product-mix pressure has had a material earnings impact., Medium priority — Medical Products execution risk: the segment is growing and improving margins, but at ¥116m of segment profit it remains too small to fully offset volatility in Techno Products..
Financial risks include Low priority — Refinancing risk is limited by a 459.1% current ratio, cash of ¥2.54bn, debt-to-equity of 0.40x, and interest coverage of 46.85x., Low-to-medium priority — Long-term loans of ¥827m and current portions of long-term loans of ¥506m should be monitored against operating cash conversion, particularly if WIP remains elevated., Low priority — Defined-benefit liabilities of ¥423m are a long-term funding obligation, although they are modest relative to ¥7.12bn of equity., Low priority — Foreign-exchange volatility: FX gains of ¥13m were modest at approximately 2.7% of operating income, but they indicate some sensitivity of ordinary income to currency movements..
Key concerns include The mismatch between flat revenue and a 29.9% operating-income decline indicates meaningful negative operating leverage at the gross-profit level., Operating-income guidance progress is 64.9% at Q3, 10.1 percentage points below the standard 75% pace, requiring a strong Q4 recovery., Net-income growth of 1.8% should not be treated as a full representation of underlying operating momentum because the effective tax rate fell to 7.4%., Monitoring of WIP conversion, inventory days, receivable days, gross-margin recovery, and Techno Products segment margin is central to assessing earnings normalization..
Investment Implications
Key takeaways include Revenue resilience was preserved at ¥4.54bn, but earnings quality at the operating level weakened as operating income fell to ¥487m., Techno Products remains the core earnings driver and its margin decline is the central fundamental issue., Medical Products provides a positive diversification trend, with both revenue and segment margin improving., Liquidity and solvency are strong, with a 71.2% equity ratio, 459.1% current ratio, and 46.85x interest coverage., Working-capital intensity is elevated, particularly due to 64.2% WIP mix and the 280-day annualized cash conversion cycle., The planned ¥35 dividend implies a conservative forecast payout ratio of approximately 18.9%..
Metrics to watch include Techno Products revenue growth and segment margin, Consolidated gross margin and operating margin, Q4 operating income required to meet the ¥750m full-year forecast, Annualized DSO, DIO, and cash conversion cycle, Work-in-process balance and WIP share of inventory, Medical Products revenue growth and segment margin, Effective tax rate normalization relative to the 7.4% Q3 level.
Regarding relative positioning, The company combines a strong, asset-backed balance sheet and low financial risk with operating performance that is currently below its own prior-year profitability level. Its 10.7% operating margin remains within a healthy manufacturing range, but the sharp year-on-year contraction and unusually long working-capital cycle create a weaker operating profile than the headline 1.8% net-income growth suggests.